Bilastine Updosing - Characterization of Underlying Mechanisms

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

December 31, 2011

Conditions
Cold Contact Urticaria
Interventions
DRUG

Bilastine

Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days

DRUG

Bilastine

Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days

Trial Locations (1)

10117

Charité-Universitätsmedizin Berlin, Berlin

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Faes Farma, S.A.

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER

NCT01271075 - Bilastine Updosing - Characterization of Underlying Mechanisms | Biotech Hunter | Biotech Hunter